Vertex Pharmaceuticals Inc (NASDAQ:VRTX) stock fell 1.94% (As on February 11, 11:29:55 AM UTC-4, Source: Google Finance) after the company reported fourth-quarter revenue that exceeded analyst estimates, but misses earning expectations. The biotechnology company also provided strong full-year 2025 guidance, signaling continued growth expectations. GAAP and Non-GAAP net income were $913 million and $1.0 billion, respectively, compared to $969 million and $1.1 billion, respectively, for the fourth quarter of 2023. Cash, cash equivalents and total marketable securities as of December 31, 2024, were $11.2 billion, compared to $13.7 billion as of December 31, 2023. The reduction in Vertex’s cash, cash equivalents and marketable securities balance compared to December 31, 2023, was due to the cash consideration paid to acquire Alpine and repurchases of the common stock pursuant to the share repurchase program, partially offset by positive cash flows provided by other operating activities.

Moreover, Vertex increased its estimates for the number of people with cystic fibrosis in the U.S., Europe, Australia, and Canada from approximately 92,000 to approximately 94,000. Vertex secured U.S. Food and Drug Administration (FDA) approval on December 20, 2024, for ALYFTREK, the once-daily next-in-class combination CFTR modulator for the treatment of people with CF ages 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK, which includes a total of 303 CFTR mutations. Additional regulatory reviews are underway for ALYFTREK in the United Kingdom (U.K.), European Union (EU), Canada, Switzerland, Australia and New Zealand. On December 20, 2024, Vertex received FDA approval for the expanded use of TRIKAFTA in patients with 94 additional non-F508del CFTR mutations.

VRTX in the fourth quarter of FY 24 has reported the adjusted earnings per share of $3.98, missing the analysts’ estimates for the adjusted earnings per share of $4.02. The company had reported the adjusted revenue growth of 16 percent to $2.91 billion in the fourth quarter of FY 24, beating the analysts’ estimates for revenue of $2.79 billion. This is primarily driven by the continued performance of TRIKAFTA^®/KAFTRIO^®. Net product revenue increased 17% to $1.84 billion in the U.S. due to continued strong patient demand and higher net realized pricing. Net product revenue increased 14% to $1.07 billion outside the U.S. on strong patient demand, including in both established and newer markets.

Looking ahead, Vertex provided full-year 2025 revenue guidance of $11.75 billion to $12.0 billion, compared to the consensus estimate of $11.85 billion.